Dividendos de Alembic Pharmaceuticals

Dividendo controles de criterios 4/6

Alembic Pharmaceuticals es una empresa que paga dividendos con una rentabilidad actual de 0.84% que está bien cubierta por los beneficios.

Información clave

0.8%

Rentabilidad por dividendo

27%

Ratio de pago

Rentabilidad media de la industria	0.7%
Próxima fecha de pago de dividendos	n/a
Fecha ex dividendo	n/a
Dividendo por acción	n/a
Beneficios por acción	₹30.03
Rentabilidad por dividendo prevista a 3 años	1.1%

Últimas actualizaciones de dividendos

Recent updates

Results: Alembic Pharmaceuticals Limited Exceeded Expectations And The Consensus Has Updated Its Estimates

Feb 08

Subdued Growth No Barrier To Alembic Pharmaceuticals Limited (NSE:APLLTD) With Shares Advancing 25%

Jan 21

Alembic Pharmaceuticals Limited (NSE:APLLTD) Shares Could Be 21% Below Their Intrinsic Value Estimate

Jan 04

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Alembic Pharmaceuticals Limited's (NSE:APLLTD) CEO For Now

Nov 05

Here's Why Alembic Pharmaceuticals (NSE:APLLTD) Has A Meaningful Debt Burden

Aug 10

Estimating The Intrinsic Value Of Alembic Pharmaceuticals Limited (NSE:APLLTD)

Jul 20

We Think Alembic Pharmaceuticals (NSE:APLLTD) Is Taking Some Risk With Its Debt

May 05

Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Quite Sensibly

Jan 17

Are Alembic Pharmaceuticals Limited (NSE:APLLTD) Investors Paying Above The Intrinsic Value?

Dec 17

These 4 Measures Indicate That Alembic Pharmaceuticals (NSE:APLLTD) Is Using Debt Reasonably Well

Sep 23

Is There An Opportunity With Alembic Pharmaceuticals Limited's (NSE:APLLTD) 27% Undervaluation?

Sep 02

Here's Why I Think Alembic Pharmaceuticals (NSE:APLLTD) Might Deserve Your Attention Today

Jun 16

Alembic Pharmaceuticals (NSE:APLLTD) Has A Pretty Healthy Balance Sheet

May 25

Estabilidad y crecimiento de los pagos

Obteniendo datos sobre dividendos

Dividendo estable: El pago de dividendos de APLLTD ha sido volátil en los últimos 10 años.

Dividendo creciente: El pago de dividendos de APLLTD ha aumentado en los últimos 10 años.

Rentabilidad por dividendo vs. Mercado

Rentabilidad por dividendo de Alembic Pharmaceuticals vs. Mercado

¿Cómo se compara la rentabilidad por dividendo de APLLTD con la del mercado?
Segmento	Rentabilidad por dividendo
Empresa (APLLTD)	0.8%
Suelo de mercado 25% (IN)	0.3%
Techo de mercado 25% (IN)	1.2%
Media de la industria (Pharmaceuticals)	0.7%
Previsión de analistas en 3 años (APLLTD)	1.1%

Dividendo destacado: El dividendo de APLLTD(0.84%) es más alto que el 25% inferior de los pagadores de dividendos del mercado Indian (0.27%).

Alto dividendo: El (0.84%) del dividendo de APLLTD es bajo en comparación con el 25% de los principales pagadores de dividendos del mercado Indian (1.22%).

Pago de beneficios a los accionistas

Cobertura de los beneficios: Con su razonablemente bajo ratio de pago (26.7%), los pagos de dividendos de APLLTD están bien cubiertos por los beneficios.

Pago en efectivo a los accionistas

Cobertura de flujo de caja: Con su actual ratio de pago en efectivo (77%), los pagos de dividendos de APLLTD están cubiertos por los flujos de caja.

Dividendos de Alembic Pharmaceuticals

Dividendo controles de criterios 4/6

Información clave

Últimas actualizaciones de dividendos

Upcoming dividend of ₹8.00 per share at 1.2% yield

Upcoming dividend of ₹10.00 per share

Upcoming dividend of ₹14.00 per share

Recent updates

Alembic Pharmaceuticals Limited to Report Q4, 2024 Results on May 09, 2024

Price target increased by 8.4% to ₹933

Consensus EPS estimates increase by 14%

Results: Alembic Pharmaceuticals Limited Exceeded Expectations And The Consensus Has Updated Its Estimates

Price target increased by 7.4% to ₹827

Third quarter 2024 earnings: Revenues in line with analyst expectations

Subdued Growth No Barrier To Alembic Pharmaceuticals Limited (NSE:APLLTD) With Shares Advancing 25%

Alembic Pharmaceuticals Limited to Report Q3, 2024 Results on Feb 05, 2024

Investor sentiment improves as stock rises 17%

Is Alembic Pharmaceuticals (NSE:APLLTD) A Risky Investment?

Alembic Pharmaceuticals Receives Various Us Food & Drug Administration Product Approvals

Alembic Pharmaceuticals Limited Appoints Pradeep Chakravarty as Head - Global Quality

Alembic Pharmaceuticals Limited Announces Management Changes

Alembic Pharmaceuticals Limited Announces Management Changes

Alembic Pharmaceuticals Limited to Report Q2, 2024 Results on Nov 07, 2023

Here's Why Alembic Pharmaceuticals (NSE:APLLTD) Can Manage Its Debt Responsibly

Alembic Pharmaceuticals Limited Announces Resignation of Jesal Shah as Head - Strategy

Alembic Pharmaceuticals Limited Announces That Mr. Nilesh Wadhwa, Head - International Business & Strategy (Formulations Business Development Division), Is Designated as Senior Management Personnel

Price target increased by 10% to ₹659

First quarter 2024 earnings released: EPS: ₹6.14 (vs ₹3.35 loss in 1Q 2023)

Alembic Pharmaceuticals Limited to Report Q1, 2024 Results on Aug 04, 2023

Upcoming dividend of ₹8.00 per share at 1.2% yield

Full year 2023 earnings: EPS exceeds analyst expectations

Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Quite Sensibly

Alembic Pharmaceuticals Limited, Annual General Meeting, Aug 04, 2023

Full year 2023 earnings: EPS exceeds analyst expectations

Alembic Pharmaceuticals Limited Approves the Appointment of Jai Diwanji as an Independent Director

A Look At The Fair Value Of Alembic Pharmaceuticals Limited (NSE:APLLTD)

Is Alembic Pharmaceuticals (NSE:APLLTD) A Risky Investment?

Consensus EPS estimates fall by 19%

Third quarter 2023 earnings released: EPS: ₹6.20 (vs ₹8.98 in 3Q 2022)

Consensus EPS estimates fall by 11%

Alembic Pharmaceuticals Limited Announces Company Secretary and Compliance Officer Changes

Alembic Pharmaceuticals Receives USFDA Tentative Approval for Acalabrutinib Capsules, 100 Mg

Alembic Pharmaceuticals Limited Receives Final Approval from the US Food & Drug Administration

Alembic Pharmaceuticals Limited (NSE:APLLTD) Shares Could Be 21% Below Their Intrinsic Value Estimate

Now 20% undervalued after recent price drop

Alembic Pharmaceuticals Limited Receives USFDA Final Approval for DesonideCream, 0.05%

Alembic Pharmaceuticals Receives USFDA Final Approval for Diclofenac Sodium Topical Solution USP, 2% w/w

Alembic Pharmaceuticals Receives USFDA Final Approval for Nifedipine Extended-Release Tablets USP, 30 Mg, 60 Mg and 90 Mg

Consensus forecasts updated

Insufficient new directors

Alembic Pharmaceuticals Limited Receives US FDA Final Approval for Cyclophosphamide Capsules, 25 Mg and 50 Mg

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Alembic Pharmaceuticals Limited's (NSE:APLLTD) CEO For Now

Investor sentiment improved over the past week

Alembic Pharmaceuticals Receives Usfda Final Approval for Mesalamine Extended-Release Capsules Usp, 0.375 G

Alembic Pharmaceuticals Limited to Report Q2, 2023 Results on Nov 11, 2022

Alembic Pharmaceuticals Limited (Alembic) Receives Final Approval from the Us Food & Drug Administration

Alembic Pharmaceuticals Limited Announces Successful Completion of USFDA Inspection at Alembic Pharmaceuticals' Bioequivalence Facility at Vadodara

Alembic Pharmaceuticals Limited, Annual General Meeting, Nov 11, 2022

Alembic Pharmaceuticals Limited Receives; U.S. Food & Drug Administration Final Approval for Chlorthalidone Tablets USP, 25 Mg and 50 Mg

Consensus EPS estimates fall by 28%

Upcoming dividend of ₹10.00 per share

Here's Why Alembic Pharmaceuticals (NSE:APLLTD) Has A Meaningful Debt Burden

Price target decreased to ₹734

First quarter 2023 earnings released: ₹3.35 loss per share (vs ₹8.37 profit in 1Q 2022)

Alembic Pharmaceuticals Limited to Report Q1, 2023 Results on Aug 04, 2022

Estimating The Intrinsic Value Of Alembic Pharmaceuticals Limited (NSE:APLLTD)

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Alembic Pharmaceuticals Receives US Food & Drug Administration Tentative Approval for Dasatinib Tablets, 20 Mg, 50 Mg, 70 Mg, 80 Mg, 100 Mg, and 140 Mg

Alembic Pharmaceuticals Limited Receives USFDA Final Approval for Pirfenidone Tablets

Alembic Pharmaceuticals Limited Announces USFDA Final Approval for Arformoterol Tartrate Inhalation Solution, 15 Mcg (Base)/2 ML Unit-Dose Vial

We Think Alembic Pharmaceuticals (NSE:APLLTD) Is Taking Some Risk With Its Debt

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Insufficient new directors

Alembic Pharmaceuticals Limited to Report Q4, 2022 Results on May 02, 2022

Alembic Pharmaceuticals Limited Receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg

Alembic Pharmaceuticals Limited Receives Tentative Approval from US Food & Drug Administration for Dabigatran Etexilate Capsules, 75 Mg, 110 Mg, and 150 Mg

Alembic Pharmaceuticals Limited (NSEI:APLLTD) acquired remaining 40% stake in Aleor Dermaceuticals Limited from Orbicular Pharmaceutical Technologies Private Limited.

Alembic Pharmaceuticals Limited (NSEI:APLLTD) acquired remaining 40% stake in Aleor Dermaceuticals Limited from Orbicular Pharmaceutical Technologies Private Limited.

Alembic Pharmaceuticals Limited Appoints Ashok Barat as an Independent Director